At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
Vaccination with Fluval AB suspension for injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 μgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects
In Brief
A Phase 4 clinical trial evaluating Vaccination with Fluval AB suspension for injection for Influenza Prophylaxis. Completed, enrolled 120 participants across 3 sites.
Detailed Summary
To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Prophylaxis
CountriesHungary
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartAug 2013
Primary CompletionSep 2013
TodayJul 2026
First PostedMay 29, 2013
Enrollment StartAug 22, 2013
Primary CompletionSep 17, 2013
TodayJul 2, 2026
Enrollment to primary: 25 daysPosted 13.1 years ago
Interventions
Vaccination with Fluval AB suspension for injectionbiological
Single intramuscular injection with Fluval AB suspension for injection in both age groups